Shares of Acadia Pharmaceuticals rocketed Monday after the biotech company said its psychosis treatment met its key goal in a Phase 3 test. The drug already sells under the name Nuplazid.
The post Why This Biotech Stock Just Rocketed 64% After Hitting A 4-Year High appeared first on Investor’s Business Daily.
This article does not constitute investment advice. We are not affiliated or responsible for content hosted on 3rd-party sites in any way.